U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593209) titled 'First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2' on May 07.
Brief Summary: Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.
Study Start Date: May 01
Study Type: OBSERVATIONAL
Condition:
Malignant Tumor
Intervention:
DEVICE: 68Ga- DOTA-EphA2 PET/C...